Hadasit Bio-Holdings Ltd (HSITF)
USD 0.12
(0.0%)
USD 0.12
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 2.12 Million ILS | -45.1% |
| 2022 | 3.87 Million ILS | 436.84% |
| 2021 | 722 Thousand ILS | -83.1% |
| 2020 | 4.27 Million ILS | 9.23% |
| 2019 | 3.91 Million ILS | 278.61% |
| 2018 | 1.03 Million ILS | -86.78% |
| 2017 | 7.81 Million ILS | -0.32% |
| 2016 | 7.83 Million ILS | -5.69% |
| 2015 | 8.3 Million ILS | -19.38% |
| 2014 | 10.3 Million ILS | 4.41% |
| 2013 | 9.87 Million ILS | 34.76% |
| 2012 | 7.32 Million ILS | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 2.71 Million ILS | 0.0% |
| 2024 Q1 | 2.71 Million ILS | 27.4% |
| 2023 Q1 | 3.72 Million ILS | -3.9% |
| 2023 Q4 | 2.12 Million ILS | 0.0% |
| 2023 FY | 2.12 Million ILS | -45.1% |
| 2023 Q3 | 2.12 Million ILS | -42.87% |
| 2023 Q2 | 3.72 Million ILS | 0.0% |
| 2022 Q2 | 1.09 Million ILS | 0.0% |
| 2022 FY | 3.87 Million ILS | 436.84% |
| 2022 Q4 | 3.87 Million ILS | 0.0% |
| 2022 Q3 | 3.87 Million ILS | 253.65% |
| 2022 Q1 | 1.09 Million ILS | 51.8% |
| 2021 FY | 722 Thousand ILS | -83.1% |
| 2021 Q4 | 722 Thousand ILS | 0.0% |
| 2021 Q2 | 1.11 Million ILS | 0.0% |
| 2021 Q3 | 722 Thousand ILS | -35.19% |
| 2021 Q1 | 1.11 Million ILS | -73.92% |
| 2020 FY | 4.27 Million ILS | 9.23% |
| 2020 Q2 | 2.61 Million ILS | 0.0% |
| 2020 Q3 | 4.27 Million ILS | 63.62% |
| 2020 Q4 | 4.27 Million ILS | 0.0% |
| 2020 Q1 | 2.61 Million ILS | -33.24% |
| 2019 Q3 | 3.91 Million ILS | 481.13% |
| 2019 Q4 | 3.91 Million ILS | 0.0% |
| 2019 Q1 | 673 Thousand ILS | -34.85% |
| 2019 FY | 3.91 Million ILS | 278.61% |
| 2019 Q2 | 673 Thousand ILS | 0.0% |
| 2018 Q1 | 2.73 Million ILS | -64.95% |
| 2018 FY | 1.03 Million ILS | -86.78% |
| 2018 Q3 | 1.03 Million ILS | -71.27% |
| 2018 Q2 | 3.59 Million ILS | 31.3% |
| 2018 Q4 | 1.03 Million ILS | 0.0% |
| 2017 FY | 7.81 Million ILS | -0.32% |
| 2017 Q1 | 3.88 Million ILS | -50.4% |
| 2017 Q2 | 7.38 Million ILS | 90.02% |
| 2017 Q3 | 6.95 Million ILS | -5.85% |
| 2017 Q4 | 7.81 Million ILS | 12.32% |
| 2016 Q4 | 7.83 Million ILS | 8.67% |
| 2016 FY | 7.83 Million ILS | -5.69% |
| 2016 Q3 | 7.21 Million ILS | 12.23% |
| 2016 Q2 | 6.42 Million ILS | -11.46% |
| 2016 Q1 | 7.25 Million ILS | -12.66% |
| 2015 Q1 | 10.42 Million ILS | 1.15% |
| 2015 Q4 | 8.3 Million ILS | 15.74% |
| 2015 Q2 | 7.6 Million ILS | -27.01% |
| 2015 Q3 | 7.17 Million ILS | -5.65% |
| 2015 FY | 8.3 Million ILS | -19.38% |
| 2014 FY | 10.3 Million ILS | 4.41% |
| 2014 Q3 | 9.07 Million ILS | 38.54% |
| 2014 Q2 | 6.55 Million ILS | -32.47% |
| 2014 Q1 | 9.7 Million ILS | -1.7% |
| 2014 Q4 | 10.3 Million ILS | 13.54% |
| 2013 Q1 | 622 Thousand ILS | -91.51% |
| 2013 Q4 | 9.87 Million ILS | 13.9% |
| 2013 Q3 | 8.66 Million ILS | 1.36% |
| 2013 FY | 9.87 Million ILS | 34.76% |
| 2013 Q2 | 8.55 Million ILS | 1274.6% |
| 2012 Q4 | 7.32 Million ILS | 0.0% |
| 2012 FY | 7.32 Million ILS | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | -153.716% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | 15.432% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | 58.648% |
| Evofem Biosciences, Inc. | 72.47 Million USD | 97.064% |
| GB Sciences, Inc. | 5.41 Million USD | 60.72% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | 41.94% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | -35.855% |
| Skye Bioscience, Inc. | 14.07 Million USD | 84.878% |
| Zenith Capital Corp. | 27.56 Thousand USD | -7618.815% |
| Agentix Corp. | 2.51 Million USD | 15.238% |
| Arch Therapeutics, Inc. | 9.46 Million USD | 77.519% |
| Biomind Labs Inc. | 1.49 Million USD | -41.998% |
| ContraFect Corporation | 32.53 Million USD | 93.459% |
| CSL Limited | 18.62 Billion USD | 99.989% |
| CytoDyn Inc. | 127.89 Million USD | 98.336% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | -48.41% |
| Neon Bloom, Inc. | 1.22 Million USD | -73.542% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | 97.16% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -4661.052% |
| Propanc Biopharma, Inc. | 3.85 Million USD | 44.748% |
| Regen BioPharma, Inc. | 5.45 Million USD | 61.009% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | 96.394% |
| SQZ Biotechnologies Company | 50.03 Million USD | 95.747% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | -5.864% |
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | 96.008% |
| Intellipharmaceutics International Inc. | 12 Million USD | 82.28% |
| Mesoblast Limited | 188.44 Million USD | 98.871% |
| Marizyme, Inc. | 26.67 Million USD | 92.023% |
| Genus plc | 485 Million USD | 99.561% |
| Pharming Group N.V. | 244.07 Million USD | 99.128% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | 44.0% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | 44.405% |
| IMV Inc. | 37.93 Million USD | 94.39% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | 81.933% |
| MultiCell Technologies, Inc. | 1617.67 USD | -131447.225% |
| ONE Bio Corp. | 27.49 Million USD | 92.261% |
| RVL Pharmaceuticals plc | 77.41 Million USD | 97.251% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | 97.434% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | 76.466% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | 88.437% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -1397.59% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -958.096% |
| Alpha Cognition Inc. | 7.16 Million USD | 70.299% |
| Enzolytics Inc. | 365.26 Million USD | 99.417% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 444.95 Million USD | 99.522% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | -24.154% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | 91.401% |
| Genscript Biotech Corporation | 1.32 Billion USD | 99.84% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | 77.792% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -404.782% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | 43.015% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -212.558% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | 21.524% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | 63.578% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | -7.404% |
| Adynxx, Inc. | - USD | -Infinity% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Accustem Sciences Inc. | 1.07 Million USD | -97.176% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -3079.489% |
| EV Biologics, Inc. | 2.11 Million USD | -0.611% |
| Q BioMed Inc. | 8.13 Million USD | 73.835% |
| Capstone Therapeutics Corp. | 50.26 Million USD | 95.766% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | 98.208% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| BioStem Technologies, Inc. | 15.9 Million USD | 86.62% |
| Curative Biotechnology, Inc. | 5.74 Million USD | 62.964% |
| HST Global, Inc. | 593.59 Thousand USD | -258.495% |
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -7657.081% |
| Wesana Health Holdings Inc. | 1.25 Million USD | -68.997% |
| Halberd Corporation | 728.71 Thousand USD | -192.019% |
| Resverlogix Corp. | 67.39 Million USD | 96.843% |
| Cell Source, Inc. | 15.8 Million USD | 86.537% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | 82.122% |
| GeneThera, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | 3.99 Million USD | 46.717% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -791.667% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| NovAccess Global Inc. | 7.86 Million USD | 72.929% |
| Kadimastem Ltd | 3.5 Million USD | 39.284% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | -3.726% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -357.931% |
| LadRx Corporation | 2.2 Million USD | 3.296% |
| Regen BioPharma, Inc. | 5.45 Million USD | 61.009% |
| Affymax, Inc. | 8.87 Million USD | 76.012% |
| Itoco Inc. | 1.65 Million USD | -28.724% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | 64.821% |
| Mobile Lads Corp. | 1.31 Million USD | -62.01% |
| International Stem Cell Corporation | 5.27 Million USD | 59.674% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| Bioxytran, Inc. | 3.24 Million USD | 34.513% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -4991.031% |
| Qrons Inc. | 1.48 Million USD | -42.942% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | 80.734% |
| SYBLEU INC | 681.41 Thousand USD | -212.292% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -163.108% |
| Rebus Holdings, Inc. | 5.24 Million USD | 59.405% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | 65.126% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -240.04% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | 53.911% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | 94.809% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | 90.442% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | -5.066% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | 61.154% |
| Neutra Corp. | 973.52 Thousand USD | -118.586% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | 92.666% |
| PureTech Health plc | 125.58 Million USD | 98.306% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | 43.361% |
| IXICO plc | 1.9 Million USD | -11.983% |
| IntelGenx Technologies Corp. | 20.52 Million USD | 89.634% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 97.94% |
| CSL Limited | 18.62 Billion USD | 99.989% |
| Cellectis S.A. | 249.36 Million USD | 99.147% |